Bringing the fundamentals into focus…
Back to NewAmsterdam Pharma Company N.V.
How NewAmsterdam Pharma Company N.V. stacks up
NAMS · against 342 other Healthcare companies of similar size
Growth
3/ 100
Near the bottom of its peers.
Ranked #336 of 343 · scores higher than 2% of peers
Bars: peers in each 10-point band of the growth score26 peers with a growth score of 0–9, including NAMS · Click a bar to see the companies
Why growth scores 3?
Weighted metrics compared with all Healthcare companies.Mainly because of its revenue growth, 3-year revenue growth and earnings per share growth, which are weaker than most Healthcare peers.
- slower revenue growth over the last year: weaker than 98% of peers. Revenue growth: -88.9% vs peer median 6.1%
- slower revenue growth over three years: weaker than 97% of peers. 3-year revenue growth: -39.7% vs peer median 5.8%
- The loss per share widened. Earnings per share growth: — vs peer median 9.8%
Metric by metric
Position: dot = NAMS, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | NAMS | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Revenue growthHigher is better · 343 reported | -88.9% | 6.8% | 2% | 33% | |
| Earnings per share growthHigher is better · 199 reported | Not reported | 9.8% | — | — | 33% |
| 3-year revenue growthHigher is better · 335 reported | -39.7% | 7.9% | 3% | 33% |
A metric that is not reported is left out of the score; the other weights are rescaled.
Ranking by growth score
Top 5 and the companies ranked around NAMS| Rank | Company | Market cap | Growth | Overall |
|---|---|---|---|---|
| 1 | 3.1B EUR (≈$3.4B) | 100 | 100 | |
| 2 | 1.4B USD | 99 | 73 | |
| 2 | 27.6B SEK (≈$2.8B) | 99 | 76 | |
| 2 | 2.1B USD | 99 | 96 | |
| 2 | 2.8B USD | 99 | 51 | |
| 330 | 4.6B USD | 5 | 29 | |
| 333 | 31.0B CNY (≈$4.3B) | 4 | 26 | |
| 333 | 12.8B CNY (≈$1.8B) | 4 | 44 | |
| 333 | 1.8B USD | 4 | 23 | |
| 336 | 2.3B USD | 3 | 26 | |
| 336 | 2.2B USD | 3 | 20 | |
| 338 | 9.1B CNY (≈$1.3B) | 2 | 20 | |
| 338 | 1.3B USD | 2 | 27 | |
| 340 | 12.7B CNY (≈$1.8B) | 1 | 20 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score